stockrow
Saturday 7 November 2026
Export OBX’s income statement to Excel — free account
Obsidian Therapeutics, Inc
14.02
4.42
+46.04%
Follow OBX
Alert me
| Jun '26 | Mar '26 | Dec '25 | Mar '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
— | 4.21 | 5.31 | — |
+1 more quarter Free account |
Net Debt/EBITDA |
— | 2.95 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | — | |
Debt/Equity |
— | 0.00 | 0.00 | — | |
Operating CF/Net income |
— | 1.12 | — | 0.98 | |
Capex/Depreciation |
— | 0.00 | — | (0.15) | |
Research and Development Expense of Revenue |
— | 0.00% | — | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | — | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | 0.00% | — | 0.00% | |
Free Cash Flow per Share |
— | (1.25) | — | (1.75) | |
Cash per Share |
— | 3.32 | 0.00 | 0.00 | |
Shareholders Equity per Share |
— | (15.63) | 0.00 | 0.00 | |
Interest Debt per Share |
— | 0.00 | — | 0.00 | |
Book value per Share |
— | (15.63) | 0.00 | 0.00 | |
Free Cash Flow |
— | (22.01) | — | (24.42) | |
Working Capital |
— | 48.81 | 66.15 | — | |
Capital Expenditures |
— | — | — | (0.06) | |
Net Current Asset Value |
— | (282.29) | (273.10) | — | |
| Other line items | |||||
Quick Ratio |
— | 3.86 | 5.24 | — | |
Revenue per Share |
— | 0.00 | — | 0.00 | |
Operating CF per Share |
— | (1.25) | — | (1.75) | |
Capex per Share |
— | 0.00 | — | 0.00 | |
Capex to Sales |
— | — | — | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026